Addition of Tranexamic Acid to the Tactical Combat Casualty Care Guidelines
Abstract
Traumatic hemorrhage is the leading cause of preventable death on the battlefield. A comprehensive review of the literature (as provided in this report) found that the antifibrinolytic tranexamic acid (TXA) has proven to decrease all cause mortality following major trauma. In trauma patients experiencing severe hemorrhage on the battlefield, tranexamic acid has the potential to reduce both mortality and morbidity. In light of these findings, the Defense Health Board recently approved a recommendation for the addition of tranexamic acid to the Tactical Combat Casualty Care (TCCC) guidelines.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 23, 2011
- Accession Number
- AD1029092
Entities
Organizations
- Defense Health Board